Table 2.
Medications for HBV and HCV patients in the initial 6 months after anti-hypertensive treatment (grouped by use of angiotensin converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARB] in the initial 6 months after index date)
| HBV patients | HCV patients | |||||
|---|---|---|---|---|---|---|
| Variables | All | Initial exposure | Initial non-exposure | All | Initial exposure | Initial non-exposure |
| n | 7724 | 3575 | 4149 | 7873 | 3349 | 4524 |
| ACEI (%) | 13.4 | 28.9* | 0 | 12.5 | 29.5* | 0 |
| Cumulative DDDa | 168 (84–205) | 168 (84–205) | 0 | 168 (95–200) | 168 (95–200) | 0 |
| ARB (%) | 36.6 | 79.0* | 0 | 32.5 | 76.5* | 0 |
| Cumulative DDDa | 168 (87–198) | 168 (87–198) | 0 | 168 (98–196) | 168 (98–196) | 0 |
| Aspirin (%) | 18.8 | 23.2* | 15.0 | 19.8 | 26.5* | 14.9 |
| Cumulative DDDa | 308 (97–392) | 309 (130–400) | 284 (84–386) | 330 (142–420) | 336 (168–420) | 309 (120–420) |
| Metformin (%) | 19.0 | 24.4* | 14.4 | 19.2 | 26.6* | 13.7 |
| Cumulative DDDa | 84 (39–126) | 88 (42–133) | 75 (31–105) | 89 (51–133) | 90 (57–135) | 84 (45–126) |
| Statin (%) | 12.5 | 17.1* | 8.6 | 5.9 | 8.4* | 4.1 |
| Cumulative DDDa | 74 (37–112) | 73 (37–112) | 75 (30–112) | 70 (37–112) | 68 (37–112) | 75 (35–112) |
aData are median (Q1-Q3). *p < 0.05 between initial exposure and non-exposure groups. DDD defined daily dose